A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.

Digital application Flu Hospital Influenza Nudging Prevention QR code Reminders Vaccination

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 17 05 2024
revised: 28 06 2024
accepted: 17 07 2024
medline: 28 7 2024
pubmed: 28 7 2024
entrez: 27 7 2024
Statut: aheadofprint

Résumé

Influenza vaccines are effective in decreasing hospitalizations and mortality related to influenza and its complications. However, the Vaccine Coverage Rate of influenza remains low and multifaceted efforts are required to improve it. The aim of this study was to assess the impact on influenza vaccine perception using a digital tool among outpatients and health care workers (HCWs). A study was performed among outpatients and the HCWs of 23 hospital departments from 4 hospitals affiliated to Lyon university Hospitals (France), between October 2022 and February 2023. By scanning QR (Quick Response) codes, displayed on posters for patients, their companions, as well as in the letters sent to HCWs, users accessed anonymously to a web-application (ELEFIGHT®), which provided information on influenza and invited them to initiate a discussion on influenza prevention with their physicians during the consultation. Patients were also invited to complete a questionnaire regarding their perception of influenza vaccination before and after reading the information on ELEFIGHT®. The retention rate (RR = proportion of people who remain on the page for >2 s), the conversion rate (CR = proportion of people who click on the "Call-To-Action" button) and the absolute variation (difference in the perception before/after) and relative variation (absolute change as a percentage of the initial perception) in perception regarding influenza vaccination before and after consulting the application were calculated. 3791 scans were performed by 3298 patients and/or their companions with a RR of 52% and a CR of 55.1% and 253 scans by 221 HCWs with a RR of 71.2% and a CR of 115.3%. Participants spent an average of 47 s on the application. The questionnaire on influenza vaccination perception was completed by 1533 participants (46.5%); 1390 (90.7%) maintained the same position (neutral, favorable or unfavorable) on this vaccination before and after consulting the application. The relative variations in favor of vaccination were + 7.2% (unfavorable then favorable) and + 19.8% (neutral then favorable). This study suggests that a facilitated direct access to medical information through QR codes disseminated in health settings can help nudge people to foster their awareness of influenza and its prevention. Future deployments in a similar context or to other populations could be envisaged. Other vaccine-preventable and/or chronic diseases could also be the target of similar projects as part of public health programs.

Sections du résumé

BACKGROUND BACKGROUND
Influenza vaccines are effective in decreasing hospitalizations and mortality related to influenza and its complications. However, the Vaccine Coverage Rate of influenza remains low and multifaceted efforts are required to improve it. The aim of this study was to assess the impact on influenza vaccine perception using a digital tool among outpatients and health care workers (HCWs).
METHODS METHODS
A study was performed among outpatients and the HCWs of 23 hospital departments from 4 hospitals affiliated to Lyon university Hospitals (France), between October 2022 and February 2023. By scanning QR (Quick Response) codes, displayed on posters for patients, their companions, as well as in the letters sent to HCWs, users accessed anonymously to a web-application (ELEFIGHT®), which provided information on influenza and invited them to initiate a discussion on influenza prevention with their physicians during the consultation. Patients were also invited to complete a questionnaire regarding their perception of influenza vaccination before and after reading the information on ELEFIGHT®. The retention rate (RR = proportion of people who remain on the page for >2 s), the conversion rate (CR = proportion of people who click on the "Call-To-Action" button) and the absolute variation (difference in the perception before/after) and relative variation (absolute change as a percentage of the initial perception) in perception regarding influenza vaccination before and after consulting the application were calculated.
RESULTS RESULTS
3791 scans were performed by 3298 patients and/or their companions with a RR of 52% and a CR of 55.1% and 253 scans by 221 HCWs with a RR of 71.2% and a CR of 115.3%. Participants spent an average of 47 s on the application. The questionnaire on influenza vaccination perception was completed by 1533 participants (46.5%); 1390 (90.7%) maintained the same position (neutral, favorable or unfavorable) on this vaccination before and after consulting the application. The relative variations in favor of vaccination were + 7.2% (unfavorable then favorable) and + 19.8% (neutral then favorable).
CONCLUSION CONCLUSIONS
This study suggests that a facilitated direct access to medical information through QR codes disseminated in health settings can help nudge people to foster their awareness of influenza and its prevention. Future deployments in a similar context or to other populations could be envisaged. Other vaccine-preventable and/or chronic diseases could also be the target of similar projects as part of public health programs.

Identifiants

pubmed: 39068066
pii: S0264-410X(24)00823-5
doi: 10.1016/j.vaccine.2024.126160
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126160

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nagham Khanafer, Florence Ader, Frédéric Berard, Françoise Bouhour, Roland Chapurlat, Sybil Charriere, Cyrille Confavreux, Gilles Devouassoux, Emmanuel Disse, Jean-Pierre Fauvel, Denis Fouque, Herve Ghesquieres, Sophie Hyvert, Anne Jolivot, Gilles Leboucher, Catherine Lombard, Géraldine Martin-Gaujard, Jean-Francois Mornex, Marc Nicolino, Nathalie Obadia, Gérald Raverot, Philippe Reix, Alain Ruffion, Pascal Seve, Eric Truy, Fabien Zoulim and Philippe Vanhems have no conflicts of interest related to this study to declare. Catherine Planckaert, Rym Bouhalila, Camille Mena and Nadège Trehet Mandel have been mandated and paid by the HCL. Sylvain Oudot, Margot Maligeay, Joséphine Clamens and Marie-Pierre Ayala are employed by Sanofi.

Auteurs

Nagham Khanafer (N)

Unité d'hygiène, épidémiologie et prévention, Hôpital Edouard Herriot (HEH), Hospices Civils de Lyon (HCL), Lyon, France; Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université de Lyon 1, Lyon, France. Electronic address: nagham.khanafer@chu-lyon.fr.

Sylvain Oudot (S)

Sanofi, Lyon, France.

Margot Maligeay (M)

Sanofi, Lyon, France.

Catherine Planckaert (C)

Centre de Recherche Clinique « Prévention des Maladies Osseuses », HEH, HCL, Lyon, France.

Camille Mena (C)

Centre de Recherche Clinique « Prévention des Maladies Osseuses », HEH, HCL, Lyon, France.

Nadège Trehet Mandel (NT)

Centre de Recherche Clinique « Prévention des Maladies Osseuses », HEH, HCL, Lyon, France.

Rym Bouhalila (R)

Unité d'hygiène, épidémiologie et prévention, Hôpital Edouard Herriot (HEH), Hospices Civils de Lyon (HCL), Lyon, France.

Florence Ader (F)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université de Lyon 1, Lyon, France; Département des Maladies infectieuses et tropicales, HCL, Lyon, France.

Frédéric Berard (F)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université de Lyon 1, Lyon, France; Service d'allergologie et immunologie clinique, Hôpital Lyon Sud, HCL, Pierre-Bénite, France.

Françoise Bouhour (F)

Service ENMG et pathologies neuromusculaires, Hôpital neurologique Pierre Wertheimer, HCL, Bron, France.

Roland Chapurlat (R)

Service de Rhumatologie, HEH, HCL, Lyon, France; INSERM UMR 1033, Université de Lyon 1, Lyon, France.

Sybil Charriere (S)

Fédération d'Endocrinologie, Maladies Métaboliques, Diabète, et Nutrition, Hôpital Louis Pradel, HCL, Bron, France; CarMen Laboratory, INSERM, INRAE, Université Lyon 1, Pierre Bénite, France.

Cyrille Confavreux (C)

INSERM UMR 1033, Université de Lyon 1, Lyon, France; Service de Rhumatologie Sud, Hôpital Lyon Sud, HCL, Pierre Bénite, France.

Gilles Devouassoux (G)

Service de Pneumologie, CIERA, Hôpital de la Croix Rousse, HCL, Lyon, France; CRISALIS/F-CRIN INSERM Network, Equipe VIRPATH CIRI, Inserm U1111, Université Lyon 1, Lyon, France.

Emmanuel Disse (E)

Service d'endocrinologie-Diabète-Nutrition, Hôpital Lyon Sud, HCL, Pierre Bénite, France; Université de Lyon 1, Lyon, France.

Denis Fouque (D)

Service de néphrologie, Hôpital Lyon Sud, HCL, Pierre Bénite, France.

Herve Ghesquieres (H)

Université de Lyon 1, Lyon, France; Service d'hématologie, Hôpital Lyon Sud, HCL, Pierre Bénite, France.

Sophie Hyvert (S)

Pharmacie, HEH, HCL, Lyon, France.

Anne Jolivot (A)

Service de néphrologie, HEH, HCL, Lyon, France.

Alice Durand (A)

Service d'oncologie médicale, HEH, HCL, Lyon, France.

Géraldine Martin-Gaujard (G)

Service de gériatrie, Hôpital Edouard Herriot, HCL, Lyon, France.

Jean-Francois Mornex (JF)

Universite Claude Bernard Lyon 1, INRAE, UMR754, IVPC, HCL, F-6900, Lyon, France.

Marc Nicolino (M)

Fédération d'Endocrinologie, Maladies Métaboliques, Diabète, et Nutrition, Hôpital Louis Pradel, HCL, Bron, France; Université de Lyon 1, Lyon, France.

Nathalie André-Obadia (N)

Service de Neurologie Fonctionnelle et d'Epileptologie, Hôpital neurologique Pierre Wertheimer, HCL, Bron, France.

Gérald Raverot (G)

Fédération d'Endocrinologie, Maladies Métaboliques, Diabète, et Nutrition, Hôpital Louis Pradel, HCL, Bron, France; Université de Lyon 1, Lyon, France.

Philippe Reix (P)

Université de Lyon 1, Lyon, France; Service de pneumologie, allergologie pédiatrique, Hôpital Femme-mère-enfant, HCL, Bron, France.

Alain Ruffion (A)

Service d'urologie, Hôpital Lyon Sud, HCL, Pierre Bénite, France; Centre d'innovation en cancérologie de Lyon (EA 3738 CICLY), Université Lyon 1, Lyon, France.

Pascal Seve (P)

Université de Lyon 1, Lyon, France; Service de médecine interne, Hôpital de la Croix Rousse, HCL, Lyon, France.

Ruben Hermann (R)

Université de Lyon 1, Lyon, France; Service d'ORL et Chirurgie Cervico-Faciale, HEH, HCL, Lyon, France.

Fabien Zoulim (F)

Service d'Hépatologie, Hôpital de la Croix Rousse, HCL, Lyon, France; INSERM U1052, Université Lyon 1, Lyon, France.

Joséphine Clamens (J)

Sanofi, Lyon, France.

Marie-Pierre Ayala (MP)

Sanofi, Lyon, France.

Philippe Vanhems (P)

Unité d'hygiène, épidémiologie et prévention, Hôpital Edouard Herriot (HEH), Hospices Civils de Lyon (HCL), Lyon, France; Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université de Lyon 1, Lyon, France; Inserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France.

Classifications MeSH